FDA’s recent approval for Epioxa (IVMED-80) marks a landmark moment in ophthalmology, introducing the first and only incision-free, topical drug therapy for keratoconus. Developed by Glaukos Corporation, Epioxa is expected to transform keratoconus care from a procedure-based model to a pharmacologic one, emphasizing accessibility and patient comfort after nearly a decade without new treatment options, according to GlobalData, a leading data and analytics company.

Keratoconus is a rare, progressive corneal disorder. Historically, management has relied almost exclusively on corneal cross-linking surgery, an effective but invasive intervention that limits uptake among patients deterred by pain, infection risk, or limited access to specialized ophthalmic centers.

Eleni Tokali, Pharma Analyst at GlobalData, comments: “Epioxa’s approval is a defining advance for corneal health. For the first time, patients have access to a non-surgical, drop-based therapy capable of strengthening the cornea and halting disease progression. This shift not only expands treatment accessibility but also establishes a new pharmacologic frontier for structural eye diseases traditionally confined to procedural care.”

Epioxa is a small-molecule eye drop that promotes natural cross-linking of corneal collagen, thereby reinforcing the cornea without tissue removal or ultraviolet activation. This non-invasive mechanism eliminates the pain, infection risk, and recovery period associated with the current gold-standard procedure, Photrexa, which has remained the only FDA-approved therapy since 2016.

According to GlobalData’s Pharmaceutical Intelligence Centre, Epioxa represents a pivotal shift in the keratoconus treatment landscape, aligning with the broader trend toward patient-centric, drug-based innovation in ophthalmology. The drug’s topical delivery may drive higher adherence and broader reach, particularly across regions underserved by surgical ophthalmic services.

Tokali adds: “Glaukos’s dual leadership in both procedural and pharmacologic keratoconus therapies positions the company uniquely at the intersection of device and drug innovation. Epioxa’s model could redefine expectations for future corneal therapeutics where efficacy, safety, and convenience coexist rather than compete.”

Commercial launch of Epioxa in the US is anticipated in Q1 2026, with regulatory submissions planned in Europe and Japan.

Tokali concludes: “The approval underscores Glaukos’s continued evolution from a device-centric company to a diversified ophthalmic innovator, and signals a new era for keratoconus management built on pharmacologic precision and patient empowerment.”